fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EASE study of AP 101 update of patient enrollment in Phase III trial for epidermolysis bullosa..-Amryt Pharma

Written by | 23 Apr 2020

EASE Trial of AP 101 from Amryt Pharma Update: In recent weeks, the COVID-19 pandemic has had a material impact on clinical trials globally, including patient recruitment. Given… read more.

FDA gives Emergency Use Authorisation for Allplex 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2.- Seegene

Written by | 23 Apr 2020

Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its Allplex 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel… read more.

Ultomiris to initiate a Phase III study to treat COVID-19.-Alexion Pharma

Written by | 21 Apr 2020

Alexion Pharmaceuticals, Inc.announced plans to initiate a global Phase III study to investigate Ultomiris (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are hospitalized with… read more.

New Mayzent data published in Neurology shows sustained effect in delaying disability for up to five years in secondary progressive multiple sclerosis .- Novartis

Written by | 21 Apr 2020

Novartis announced new Mayzent (siponimod) data in the April supplemental issue of Neurology, the medical journal of the American Academy of Neurology. The data build on existing clinical… read more.

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients .

Written by | 20 Apr 2020

Novartis has reached an agreement with the FDA to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the… read more.

Incyte announces initiation of phase III RUXCOVID study for Jakafi as a treatment for patients with COVID-19 associated cytokine storm.

Written by | 19 Apr 2020

Incyte announced the initiation of RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients… read more.

Abbott launches antibody test for COVID-19.

Written by | 17 Apr 2020

Abbott announced the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had… read more.

Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig as a preventive treatment across the full spectrum of migraine.

Written by | 16 Apr 2020

Novartis announced that clinical data for Aimovig (erenumab) was reported in Neurology . The data strengthens the role Aimovig as a preventive migraine treatment and confirms its real-world… read more.

Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig as a preventive treatment across the full spectrum of migraine.

Written by | 16 Apr 2020

Novartis announced that clinical data for Aimovig (erenumab) was reported in Neurology . The data strengthens the role Aimovig as a preventive migraine treatment and confirms its real-world… read more.

AstraZeneca initiates CALAVI study of Calquence to treat cytokine storm associated with COVID-19 infection.

Written by | 15 Apr 2020

AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19… read more.

Health Canada approves Spartan Cube COVID-19 test. – Spartan Bioscience

Written by | 14 Apr 2020

Spartan Bioscience announced it has received Health Canada approval for its rapid, accurate and portable COVID-19 test. Approval by Health Canada means that tests can now be shipped… read more.

Data on 53 patients treated with remdesivir through the compassionate use program is published in New England Journal of Medicine.- Gilead Sciences

Written by | 12 Apr 2020

Gilead Sciences, Inc. announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with the investigational antiviral remdesivir on an… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.